Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Controlled, Open-Label Phase III Study Evaluating the Efficacy and Safety of ZG006 for Injection Compared With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Start Date
December 12, 2025
Primary Completion Date
October 1, 2028
Completion Date
December 1, 2028
Last Updated
January 5, 2026
420
ESTIMATED participants
ZG006
DRUG
Topotecan
DRUG
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT07336732
NCT06712355
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05419076